Phaseline

Companies › Zero Point Five Therapeutics

Zero Point Five Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Infectious disease; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ZP5-9676
Broad-spectrum benzimidazole anthelmintic
TubulinPhase 3Soil-Transmitted Helminthiasis (STH)Mar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06128447ZP5-9676Phase 3Soil-Transmitted Helminthiasis (STH)Infectious diseaseMar 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

Tubulin (1)

Companies with the same targets

Roche Takeda Sichuan Kelun-Biotech Biopharmaceutical Pfizer AbbVie RemeGen Fidia Farmaceutici GSK Beijing Biostar Pharmaceuticals Urotronic

Companies built like this

Laboratorio Farmaceutico SIT srl Lallemand Pharma Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) MicuRx Jiangxi Qingfeng Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.